Voloridge Investment Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Voloridge Investment Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.83M	Sell	528,172 -211,272	-29%	-$3.09M	0.03%	566
2025 Q4	$11.8M	Buy	739,444 +226,875	+44%	+$3.22M	0.04%	534
2025 Q3	$5.66M	Buy	+512,569	New	+$5.6M	0.02%	708
2022 Q1	–	Sell	-880,583	Closed	-$20.1M	–	1359
2021 Q4	$20.1M	Buy	880,583 +253,829	+40%	+$6.01M	0.11%	261
2021 Q3	$13.9M	Buy	+626,754	New	+$9.95M	0.09%	308
2020 Q1	–	Sell	-21,322	Closed	-$432K	–	1085
2019 Q4	$432K	Buy	+21,322	New	+$196K	0.01%	851
2017 Q2	–	Sell	-251,475	Closed	-$1.85M	–	409
2017 Q1	$1.85M	Buy	+251,475	New	+$1.16M	0.05%	324

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Voloridge Investment Management's AUPH Position: Q1 2026 in Review

Voloridge Investment Management reduced its Aurinia Pharmaceuticals (AUPH) stake by 29% in Q1 2026, selling an estimated $3.09M and leaving 528,172 shares worth $7.83M. The position accounts for 0.03% of the portfolio, ranked #566.

Voloridge Investment Management first reported a position in AUPH in Q1 2017 and has held it in 7 quarters since. The position peaked at $20.1M in Q4 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

Voloridge Investment Management held 528,172 shares of Aurinia Pharmaceuticals worth $7.83M as of Q1 2026.
Voloridge Investment Management sold 211,272 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $3.09M.
Aurinia Pharmaceuticals made up 0.03% of Voloridge Investment Management's portfolio in Q1 2026, its #566 holding.
Voloridge Investment Management first reported a position in Aurinia Pharmaceuticals in Q1 2017 and has held it in 7 quarters since.
Voloridge Investment Management's Aurinia Pharmaceuticals position peaked at $20.1M in Q4 2021.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.